Navigation Links
The Virginia G. Piper Charitable Trust and Flinn Foundation launch
Date:10/17/2007

PHOENIX, Oct. 17, 2007 Two Arizona-based philanthropic organizations have committed $45 million to fund an innovative initiative to develop personalized molecular diagnostics. The ability to diagnose and treat disease based on every persons unique physiological makeup is critical to enabling physicians to improve health outcomes while at the same time reducing medical costs.

Under the Partnership for Personalized Medicine, The Virginia G. Piper Charitable Trust has committed $35 million and the Flinn Foundation has granted $10 million to bring together a wide range of resources to advance a global personalized medicine initiative.

World-renowned scientist Dr. Lee Hartwell, 2001 Nobel laureate and director of Fred Hutchinson Cancer Research Center, has been recruited to lead this effort. The Hutchinson Center, based in Seattle, is a leader in using molecular diagnostics for the early detection and clinical management of cancer and other diseases. In addition to his current position as president and director of Fred Hutchinson Cancer Research Center, he will chair the Partnership executive committee, which includes Dr. George Poste, director of the Biodesign Institute at Arizona State University, and Dr. Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute (TGen).

It is a tremendous opportunity for me to be a part of this new model for improving health while reducing health care costs that is being funded by the Piper and Flinn foundations, Hartwell said. The collaboration between TGen, the Biodesign Institute at ASU, other institutions in Arizona and Fred Hutchinson Cancer Research Center brings together enormous expertise to tackle major challenges in bringing new science and technology to disease management.

The cornerstone of the Partnership is the creation of the Virginia G. Piper Center for Personalized Diagnostics that draws upon the scientific strengths of two of the sta
'/>"/>

Contact: Galen Perry
gperry@tgen.org
602-343-8423
The Translational Genomics Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Once a Lawn Mower, a Self-made Billionaire Makes a Lasting Gift to Virginia Tech
2. West Virginia Organizes a Program to Fight Obesity
3. Indians Add to Rich Diversity of Virginia Tech
4. Virginia Tech. Shooter -Human Rights or Innocent Lives
5. Virginia Tech Shooters Mental Health Records No More Secret
6. Fire Ants are Emerging Nuisance for Virginians
7. Australian Devises Online Game Based on Virginia Tech Shootout
8. Pain Doctor in Virginia Sentenced to Five Years Imprisonment
9. Five Killed by Methane Gas on Virginia Farm
10. Trust In Doctors Can Affect Taking Medications
11. Repeated checking causes memory distrust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... By Amanda Gardner HealthDay Reporter , , ... colonoscopies frequently complain about having the procedure, which ... detect precancerous or cancerous growths. But a ... colonoscopy to the less invasive and less time-consuming ... been the standard of care for colon cancer ...
(Date:5/23/2012)... the United Kingdom have determined that azithromycin, a ... be an effective treatment option for patients suffering ... that occurs in the majority of patients following ... cause of mortality after the first year following ... repeatedly rejects the transplanted lung tissue. The syndrome ...
(Date:5/22/2012)... -- Children born with cleft lip, cleft palate ... beyond appearance. , Patients can face serious airway, ... social and psychological challenges, Laura Swibel Rosenthal, MD, ... in the June 2012 issue of Otolaryngologic ... of patients with craniofacial syndromes is complex," Rosenthal ...
(Date:5/22/2012)... -- Researchers at Barrow Neurological Institute at St. ... and why the public perceives some magic tricks ... in military tactics, marketing and sports. , Susana ... and Stephen Macknik, PhD, of Barrow,s Laboratory of ... into magic and illusions. Their most recent original ...
(Date:5/22/2012)... Richmond, Va. (May 22, 2012) Scientists ... be one step closer to developing a new ... that the targeted agents obatoclax and sorafenib kill ... when the drugs are administered individually., Recently published ... study led by Steven Grant, M.D., Shirley Carter ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Study shows antibiotic improves respiratory function in lung transplant patients 2Health News:Cleft lip/palate cause much more than cosmetic problems 2Health News:Barrow researchers use magic for discoveries 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3
... firm Anapol, Schwartz, Weiss, Cohan, Feldman and Smalley, P.C., was ... Justice,s (AAJ) executive committee at the organization,s recent annual convention ... ... August 20, 2008 -- http://www.anapolschwartz.com/attorneys/sol_weiss.shtml?ID=toplintrack20081111 [Sol H. Weiss], ...
... Aug. 20 Peer-reviewed safety and ... Stimulation (eToims(R)),successfully applied to patients suffering ... August/September issue of Electromyography and,Clinical Neurophysiology. ... associated physicians Jennifer Chu, M.D. and ...
... Inc. (Nasdaq:,EVVV) today announced that Pat Spangler, chief financial ... present at the Morgan,Stanley Global Healthcare Unplugged Conference at ... the Grand Hyatt New York located at 109 East,42nd ... To access the webcast, go to the investors, ...
... 19 The United States Agency,for International Development (USAID) is ... aid to help the millions of people in need,of assistance ... of,split yellow peas, 6,150 MT of vegetable oil, 6,320 MT ... is only one of multiple strategies USAID,is implementing to alleviate ...
... Offering Enhanced Customer Service ... ... ModernMed, http://www.ModernMed.com, announced its partnership with Dr. Neil ... patients with primary care focused on prevention and aging well.,Enhanced ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) announced today ... board of directors effective August 18. Glyn Aeppel, board,member ... Hotels and David Fuente, director and former chairman and ... class of directors whose,term of office expires at Sunrise,s ...
Other Medicine News:Health News:Anapol Schwartz Attorney Named to Executive Committee of American Association for Justice 2Health News:Positive Findings Published on Emergent Technology for Treating Chronic Pain 2Health News:USAID Expedites Emergency Food Aid to Horn of Africa 2Health News:ModernMed Announces Partnership With Dr. Neil J. Sapin, M.D. 2Health News:Sunrise Senior Living Appoints Glyn Aeppel and David Fuente to its Board 2
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... 24, 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical ... Prodrug (TAP),technology, today announced that clinical findings for ... tumors are to be,reported at the 43rd American ... place June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 ...
... 2007 /PRNewswire/ -- With enormous,investments and the ... firms need to develop effective strategies for,communicating ... communication planning and execution will gain a ... research and consulting firm Best Practices, LLC,successful ...
Other Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: